583,437 Shares in GoodRx Holdings, Inc. $GDRX Purchased by Pathway Capital Management LP

Pathway Capital Management LP acquired a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 583,437 shares of the company’s stock, valued at approximately $2,906,000. GoodRx comprises about 3.2% of Pathway Capital Management LP’s portfolio, making the stock its 6th biggest position. Pathway Capital Management LP owned about 0.16% of GoodRx as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in GDRX. Teacher Retirement System of Texas bought a new position in GoodRx in the 1st quarter worth about $218,000. Hohimer Wealth Management LLC boosted its stake in GoodRx by 8.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company’s stock worth $155,000 after purchasing an additional 2,658 shares during the period. SBI Securities Co. Ltd. boosted its stake in GoodRx by 13.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company’s stock worth $100,000 after purchasing an additional 2,748 shares during the period. Allianz Asset Management GmbH boosted its stake in GoodRx by 20.3% in the 1st quarter. Allianz Asset Management GmbH now owns 278,077 shares of the company’s stock worth $1,226,000 after purchasing an additional 46,900 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in GoodRx in the 1st quarter worth about $274,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Performance

Shares of GDRX opened at $3.44 on Friday. The company has a market cap of $1.20 billion, a PE ratio of 34.40, a price-to-earnings-growth ratio of 1.53 and a beta of 1.23. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. The stock has a 50-day moving average price of $4.16 and a 200-day moving average price of $4.33. GoodRx Holdings, Inc. has a 12-month low of $3.31 and a 12-month high of $6.42.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The business had revenue of $203.07 million for the quarter, compared to the consensus estimate of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The business’s revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.08 EPS. As a group, equities analysts forecast that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

GDRX has been the subject of a number of recent analyst reports. Raymond James Financial lowered shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $6.00 price target on shares of GoodRx in a research report on Monday, August 11th. Finally, Weiss Ratings lowered shares of GoodRx from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $5.80.

Insiders Place Their Bets

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the company’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total transaction of $95,084.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.53% of the stock is owned by insiders.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.